Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy.

We apply the magic methyl effect to improve the potency/efficacy of GAT211, the prototypic 2-phenylindole-based cannabinoid type-1 receptor (CB1R) agonist-positive allosteric modulator (ago-PAM). Introducing a methyl group at the α-position of nitro group generated two diastereomers, the greater potency and efficacy of erythro, (±)-9 vs threo, (±)-10 constitutes the first demonstration of diastereoselective CB1R-allosteric modulator interaction. Of the (±)-9 enantiomers, (-)-(S,R)-13 evidenced improved potency over GAT211 as a CB1R ago-PAM, whereas (+)-(R,S)-14 was a CB1R allosteric agonist biased toward G protein- vs β-arrestin1/2-dependent signaling. (-)-(S,R)-13 and (+)-(R,S)-14 were devoid of undesirable side effects (triad test), and (+)-(R,S)-14 reduced intraocular pressure with an unprecedentedly long duration of action in a murine glaucoma model. (-)-(S,R)-13 docked into both a CB1R extracellular PAM and intracellular allosteric-agonist site(s), whereas (+)-(R,S)-14 preferentially engaged only the latter. Exploiting G-protein biased CB1R-allosteric modulation can offer safer therapeutic candidates for glaucoma and, potentially, other diseases.

[1]  Benjamin Amendolara,et al.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids , 2020, Pharmacology Biochemistry and Behavior.

[2]  J. Cheer,et al.  Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement. , 2020, Current opinion in pharmacology.

[3]  M. Clark,et al.  Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases , 2020, International journal of molecular sciences.

[4]  G. Thakur,et al.  Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. , 2020, Bioorganic & medicinal chemistry.

[5]  J. Middleton,et al.  Positive allosteric modulation of the cannabinoid type-1 receptor (CB1R) in periaqueductal gray (PAG) antagonizes anti-nociceptive and cellular effects of a mu-opioid receptor agonist in morphine-withdrawn rats , 2020, Psychopharmacology.

[6]  M. Kolko,et al.  Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment , 2020, Journal of ophthalmology.

[7]  J. Crystal,et al.  Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward , 2020, Frontiers in Molecular Neuroscience.

[8]  Naga Rajiv Lakkaniga,et al.  The Exploration of Chirality for Improved Druggability within the Human Kinome. , 2020, Journal of medicinal chemistry.

[9]  G. Thakur,et al.  Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation , 2020, Molecules.

[10]  K. Mackie,et al.  Application of Fluorine- And Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of CB1 Receptor Positive Allosteric Modulators. , 2019, Journal of medicinal chemistry.

[11]  R. Słomski,et al.  Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities , 2019, International journal of molecular sciences.

[12]  P. Kalivas,et al.  The loss of NMDAR‐dependent LTD following cannabinoid self‐administration is restored by positive allosteric modulation of CB1 receptors , 2019, Addiction biology.

[13]  D. Rosenbaum,et al.  Structure of an allosteric modulator bound to the CB1 cannabinoid receptor , 2019, Nature Chemical Biology.

[14]  G. Thakur,et al.  Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling , 2019, Front. Mol. Neurosci..

[15]  Sumanta Garai,et al.  Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. , 2019, ACS medicinal chemistry letters.

[16]  M. Demitrack,et al.  APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty , 2019, Pain practice : the official journal of World Institute of Pain.

[17]  G. Thakur,et al.  Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model , 2019, Neuropharmacology.

[18]  P. Morales,et al.  Structural Insights into CB1 Receptor Biased Signaling , 2019, International journal of molecular sciences.

[19]  D. Kendall,et al.  Translational potential of allosteric modulators targeting the cannabinoid CB1 receptor , 2018, Acta Pharmacologica Sinica.

[20]  H. Choo,et al.  Discovery of β-Arrestin Biased Ligands of 5-HT7R. , 2018, Journal of medicinal chemistry.

[21]  S. Schulz,et al.  Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization , 2018, Science Signaling.

[22]  J. McCorvy,et al.  Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. , 2018, Journal of medicinal chemistry.

[23]  A. Lichtman,et al.  Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity , 2018, Drug metabolism reviews.

[24]  K. Mackie,et al.  Enantiomer‐specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons , 2017, Pharmacological research.

[25]  A. CairnsElizabeth,et al.  The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. , 2017 .

[26]  K. Mackie,et al.  Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence , 2017, Biological Psychiatry.

[27]  A. Lichtman,et al.  Apparent CB1 Receptor Rimonabant Affinity Estimates: Combination with THC and Synthetic Cannabinoids in the Mouse In Vivo Triad Model , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[28]  Sumanta Garai,et al.  Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β-Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators , 2017 .

[29]  Thuy-Ai T Nguyen,et al.  Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor , 2017, Medicinal research reviews.

[30]  A. Makriyannis,et al.  Functional selectivity at G‐protein coupled receptors: Advancing cannabinoid receptors as drug targets , 2017, Biochemical pharmacology.

[31]  Hope D. Anderson,et al.  Cannabinoid signaling in health and disease. , 2017, Canadian journal of physiology and pharmacology.

[32]  M. Glass,et al.  Cannabinoid CB1 and CB2 Receptor Signaling and Bias , 2017, Cannabis and cannabinoid research.

[33]  J. Deschamps,et al.  Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. , 2017, ACS chemical neuroscience.

[34]  A. Bayoumi,et al.  Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology , 2017, Biomolecules & therapeutics.

[35]  T. Gamage,et al.  CB1 Allosteric Modulator Org27569 Is an Antagonist/Inverse Agonist of ERK1/2 Signaling , 2016, Cannabis and cannabinoid research.

[36]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[37]  G. Thakur,et al.  Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target , 2016, Expert opinion on drug discovery.

[38]  Nestor Etxebarria,et al.  Targeting the endocannabinoid system: future therapeutic strategies. , 2016, Drug discovery today.

[39]  R. Laprairie,et al.  Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease , 2016, Molecular Pharmacology.

[40]  W. Baldridge,et al.  The Endocannabinoid System as a Therapeutic Target in Glaucoma , 2016, Neural plasticity.

[41]  Alexander D. MacKerell,et al.  CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.

[42]  A. Lichtman,et al.  A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects , 2015, Neuropsychopharmacology.

[43]  Kari A. Johnson,et al.  Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents , 2015, Neuron.

[44]  L. Bohn,et al.  A Novel Method for Analyzing Extremely Biased Agonism at G Protein–Coupled Receptors , 2015, Molecular Pharmacology.

[45]  Shailesh N Mistry,et al.  Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics , 2015, British journal of pharmacology.

[46]  A. Christopoulos,et al.  Biased Agonism at G Protein‐Coupled Receptors: The Promise and the Challenges—A Medicinal Chemistry Perspective , 2014, Medicinal research reviews.

[47]  S. Laporte,et al.  Allosteric and Biased G Protein-Coupled Receptor Signaling Regulation: Potentials for New Therapeutics , 2014, Front. Endocrinol..

[48]  P. Piazza,et al.  Pregnenolone Can Protect the Brain from Cannabis Intoxication , 2014, Science.

[49]  Klaus Schulten,et al.  Rapid parameterization of small molecules using the force field toolkit , 2013, J. Comput. Chem..

[50]  Heike Schönherr,et al.  Profound methyl effects in drug discovery and a call for new C-H methylation reactions. , 2013, Angewandte Chemie.

[51]  S. Dewire,et al.  Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. , 2013, Journal of medicinal chemistry.

[52]  Jing Zhang,et al.  Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences , 2013 .

[53]  S. Le Grand,et al.  Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. , 2013, Journal of chemical theory and computation.

[54]  Guodong Liu,et al.  A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[55]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges , 2012, J. Chem. Inf. Model..

[56]  R. N. Takahashi,et al.  Anti-inflammatory lipoxin A4 is an endogenous allosteric enhancer of CB1 cannabinoid receptor , 2012, Proceedings of the National Academy of Sciences.

[57]  W. L. Jorgensen,et al.  Methyl effects on protein-ligand binding. , 2012, Journal of medicinal chemistry.

[58]  Arthur Christopoulos,et al.  A simple method for quantifying functional selectivity and agonist bias. , 2012, ACS chemical neuroscience.

[59]  D. Janero.  Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists , 2012, Expert opinion on emerging drugs.

[60]  B. Hudson,et al.  Indirect Sympatholytic Actions at β-Adrenoceptors Account for the Ocular Hypotensive Actions of Cannabinoid Receptor Agonists , 2011, Journal of Pharmacology and Experimental Therapeutics.

[61]  Hyeon Joo,et al.  OPM database and PPM web server: resources for positioning of proteins in membranes , 2011, Nucleic Acids Res..

[62]  E. Barreiro,et al.  The methylation effect in medicinal chemistry. , 2011, Chemical reviews.

[63]  Michael G. Anderson,et al.  Anterior segment dysgenesis and early-onset glaucoma in nee mice with mutation of Sh3pxd2b. , 2011, Investigative ophthalmology & visual science.

[64]  W C Guida,et al.  The significance of chirality in drug design and development. , 2011, Current topics in medicinal chemistry.

[65]  Alexander D. MacKerell,et al.  Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. , 2010, The journal of physical chemistry. B.

[66]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[67]  R. Ross.  Allosterism and cannabinoid CB(1) receptors: the shape of things to come. , 2007, Trends in pharmacological sciences.

[68]  W. Im,et al.  Automated Builder and Database of Protein/Membrane Complexes for Molecular Dynamics Simulations , 2007, PloS one.

[69]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[70]  K. Mackie,et al.  Depolarization‐induced suppression of excitation in murine autaptic hippocampal neurones , 2005, The Journal of physiology.

[71]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[72]  A. Christopoulos,et al.  Allosteric Modulation of the Cannabinoid CB1 Receptor , 2005, Molecular Pharmacology.

[73]  L. Petrocellis,et al.  The endocannabinoid system and its therapeutic exploitation , 2004, Nature Reviews Drug Discovery.

[74]  J. Traynor,et al.  The [35S]GTPγS binding assay: approaches and applications in pharmacology , 2003 .

[75]  K. Green,et al.  Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. , 1997, Ophthalmic research.

[76]  K. McCarthy,et al.  Characterization and Partial Purification of AIM: A Plasma Protein That Induces Rat Cerebral Type 2 Astroglia from Bipotential Glial Progenitors , 1991, Journal of neurochemistry.

[77]  C. Stevens,et al.  Excitatory and inhibitory autaptic currents in isolated hippocampal neurons maintained in cell culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[79]  D. Potter,et al.  Chemical transmission between rat sympathetic neurons and cardiac myocytes developing in microcultures: evidence for cholinergic, adrenergic, and dual-function neurons. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[80]  R. Pertwee.  The ring test: a quantitative method for assessing the ‘cataleptic’ effect of cannabis in mice , 1972, British journal of pharmacology.

[81]  L. Bohn,et al.  Approaches to Assess Biased Signaling at the CB1R Receptor. , 2017, Methods in enzymology.

[82]  Sumanta Garai,et al.  Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. , 2017, Methods in enzymology.

[83]  V. Di Marzo.  Targeting the endocannabinoid system: to enhance or reduce? , 2008 .

[84]  S. Podos,et al.  Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. , 2003, Archives of ophthalmology.